CMTA and Pharnext Enter Biomarker Research Collaboration
…biopharmaceutical company pioneering new approaches to develop innovative drug combinations based on big genomics data and artificial intelligence, today announced a research collaboration with the United States patient advocacy group,…
CMT2F Research
…the research projects the CMTA is currently funding. Support CMT Research View the projects currently active or recently completed in the CMT2F drug development pipeline. CMT2F RESEARCH PROJECTS PROJECT GOAL:…
Research Triangle Area, NC CMTA Branch Meeting
02/17/2024 @ 10:30 am – 11:30 am – Please join us (virtual) for the Research Triangle Area, NC CMTA Branch meeting on Saturday, February 17th at 10:30 am Eastern Time. During our meeting, Dr. Katherine Forsey, CMTA’s Chief Research Officer. Katherine will provide an overview of CMTA-STAR Research and the Patients as Partners in Research Initiative. There will be time for questions with […]
CMT2S Research
…we share with you the research projects the CMTA is currently funding. Support CMT Research View the projects currently active or recently completed in the CMT2S drug development pipeline. CMT2S…
New Gene Therapy, Type 1/Type 4 Research Projects Approved
The Charcot-Marie Tooth Association today announced another $335,000 in grants to top CMT scientists leading the field in CMT Type 1 research. The grants represent the CMTA’s commitment to finding…
The CMTA Is Accelerating Research Through Gene Therapy
…explore gene therapy in CMT by expanding our Strategy to Accelerate Research (STAR) program and our STAR Advisory Board. In CMT, the genetic causes for many types of CMT are…
Our Mission and History
…group of patients, their families, clinicians, and researchers united with one mission: to eliminate Charcot-Marie-Tooth disease (CMT). This group would launch what is now the Charcot-Marie-Tooth Association. Visit our About…
CMTA Centers of Excellence
…to participate in critically needed CMT research, including CMTA-supported research conducted by the Inherited Neuropathies Consortium (INC). CMTA Partners with the Inherited Neuropathies Consortium CMTA has many research and biopharma…
Another $500,000 Pledge to Type 2 Research!
Bruce Chizen, a special advisor to the Board of Directors, will match donations to CMT2 research on a one-to-one basis, up to $500,000. The former Adobe Systems CEO tells us…
The CMTA Announces the Funding of a New Research Study for CMT2A
This new grant is one of more than 70 grants the CMTA has funded through its Strategy to Accelerate Research since 2008. The CMTA announces the funding of a clinical…